Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: Evidence from the MIST2 randomised controlled trial.
The MIST2 trial showed that combined intrapleural use of tissue plasminogen activator (t-PA) and DNase was effective when compared to single agents or placebo. However, the treatment costs are significant and overall cost-effectiveness of combined therapy remains unclear.An economic evaluation of th...
Principais autores: | Luengo-Fernandez, R, Penz, E, Dobson, M, Psallidas, I, Nunn, A, Maskell, N, Rahman, N |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
European Respiratory Society Publications
2019
|
Registros relacionados
-
Intrapleural use of tissue plasminogen activator and DNase in pleural infection
por: Rahman, N, et al.
Publicado em: (2011) -
Intrapleural use of tissue plasminogen activator and DNase in pleural infection.
por: Rahman, N, et al.
Publicado em: (2011) -
The biological effect of tissue plasminogen (t-PA) activator and DNase intrapleural delivery in pleural infection patients
por: Kanellakis, N, et al.
Publicado em: (2018) -
PRIMARY RESULT OF THE SECOND MULTICENTRE INTRAPLEURAL SEPSIS (MIST2) TRIAL; RANDOMISED TRIAL OF INTRAPLEURAL TPA AND DNASE IN PLEURAL INFECTION
por: Rahman, N, et al.
Publicado em: (2009) -
Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients
por: Kanellakis, N, et al.
Publicado em: (2019)